“…Thus, it appears that Chk2 inactivation leads to a decreased somatic hypermutation in this model system, in contrast to an increased hypermutation detectable in the same assay in case of Chk1 inhibition. 27 To assess whether Chk2 inhibition also leads to decreased hypermutation of the endogenous Ig loci in Burkitt lymphoma cell lines, and to prevent potential EBV effects on checkpoint control, we used the well established EBV-negative RAMOS cell system. 33,34 Here, introduction of deleterious mutations into the Ig genes leads to a loss of surface IgM expression that can be measured by FACS analyses.…”